Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 53 articles:
HTML format
Text format



Single Articles


    May 2019
  1. MURAMATSU H, Sumitomo M, Morinaga S, Kajikawa K, et al
    Targeting lactate dehydrogenaseA promotes docetaxelinduced cytotoxicity predominantly in castrationresistant prostate cancer cells.
    Oncol Rep. 2019 May 24. doi: 10.3892/or.2019.7171.
    PubMed     Text format     Abstract available


  2. XU SG, Yu JJ, Shi Q, Niu Q, et al
    Conditionally replicative adenovirus carrying shRNA targeting EZH2 inhibits prostate cancer growth and invasion.
    Oncol Rep. 2019 May 13. doi: 10.3892/or.2019.7157.
    PubMed     Text format     Abstract available


    April 2019
  3. ZHANG J, Wang J, Luan T, Zuo Y, et al
    Deubiquitinase USP9X regulates the invasion of prostate cancer cells by regulating the ERK pathway and mitochondrial dynamics.
    Oncol Rep. 2019 Apr 18. doi: 10.3892/or.2019.7131.
    PubMed     Text format     Abstract available


    March 2019
  4. SUN W, Li L, Du Z, Quan Z, et al
    Combination of phospholipase Cepsilon knockdown with GANT61 sensitizes castrationresistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Oncol Rep. 2019 Mar 7. doi: 10.3892/or.2019.7054.
    PubMed     Text format     Abstract available


    January 2019
  5. ZHANG N, Su P, Li X, Xi J, et al
    Downregulated Kruppellike factor 4 expression is associated with the aggressiveness of prostate cancer.
    Oncol Rep. 2019 Jan 22. doi: 10.3892/or.2019.6975.
    PubMed     Text format     Abstract available


    December 2018
  6. LIAO W, Liu J, Liu B, Huang X, et al
    JIB04 induces cell apoptosis via activation of the p53/Bcl2/caspase pathway in MHCC97H and HepG2 cells.
    Oncol Rep. 2018;40:3812-3820.
    PubMed     Text format     Abstract available


    November 2018
  7. KAWAN MA, Kyrou I, Ramanjaneya M, Williams K, et al
    Involvement of the glutamine RFamide peptide and its cognate receptor GPR103 in prostate cancer.
    Oncol Rep. 2018 Nov 27. doi: 10.3892/or.2018.6893.
    PubMed     Text format     Abstract available


  8. YE J, Chu C, Chen M, Shi Z, et al
    TROAP regulates prostate cancer progression via the WNT3/survivin signalling pathways.
    Oncol Rep. 2018 Nov 9. doi: 10.3892/or.2018.6854.
    PubMed     Text format     Abstract available


  9. TAKAO A, Yoshikawa K, Karnan S, Ota A, et al
    Generation of PTENknockout (/) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling.
    Oncol Rep. 2018;40:2455-2466.
    PubMed     Text format     Abstract available


  10. WU S, Huang J, Hui K, Yue Y, et al
    2'Hydroxyflavanone inhibits epithelialmesenchymal transition, and cell migration and invasion via suppression of the Wnt/betacatenin signaling pathway in prostate cancer.
    Oncol Rep. 2018;40:2836-2843.
    PubMed     Text format     Abstract available


    October 2018
  11. TANG Y, Wu B, Huang S, Peng X, et al
    Downregulation of miR5053p predicts poor bone metastasisfree survival in prostate cancer.
    Oncol Rep. 2018 Oct 25. doi: 10.3892/or.2018.6826.
    PubMed     Text format     Abstract available


  12. WANG H, Huang W, Yu X, Li W, et al
    Two prostate cancerassociated polymorphisms in the 3'UTR of IGF1R influences prostate cancer susceptibility by affecting miRNA binding.
    Oncol Rep. 2018 Oct 22. doi: 10.3892/or.2018.6810.
    PubMed     Text format     Abstract available


  13. NASSER MI, Han T, Adlat S, Tian Y, et al
    Inhibitory effects of Schisandrin B on human prostate cancer cells.
    Oncol Rep. 2018 Oct 15. doi: 10.3892/or.2018.6791.
    PubMed     Text format     Abstract available


  14. MITRAN B, Andersson KG, Lindstrom E, Garousi J, et al
    Affibodymediated imaging of EGFR expression in prostate cancer using radiocobaltlabeled DOTAZEGFR:2377.
    Oncol Rep. 2018 Oct 15. doi: 10.3892/or.2018.6792.
    PubMed     Text format     Abstract available


  15. GAN BL, Zhang LJ, Gao L, Ma FC, et al
    Downregulation of miR2245p in prostate cancer and its relevant molecular mechanism via TCGA, GEO database and in silico analyses.
    Oncol Rep. 2018 Oct 3. doi: 10.3892/or.2018.6766.
    PubMed     Text format     Abstract available


  16. ZHANG P, Li Y, Tang X, Guo R, et al
    Zinc enhances chemosensitivity to paclitaxel in PC3 prostate cancer cells.
    Oncol Rep. 2018;40:2269-2277.
    PubMed     Text format     Abstract available


  17. DONG Q, Lv C, Zhang G, Yu Z, et al
    Impact of RNAbinding motif 3 expression on the whole transcriptome of prostate cancer cells: An RNA sequencing study.
    Oncol Rep. 2018;40:2307-2315.
    PubMed     Text format     Abstract available


  18. ULLAH K, Addai Peprah F, Yu F, Shi H, et al
    The application of prostate specific membrane antigen in CARTcell therapy for treatment of prostate carcinoma (Review).
    Oncol Rep. 2018 Oct 1. doi: 10.3892/or.2018.6758.
    PubMed     Text format     Abstract available


    August 2018
  19. WANG J, Yang X, Li R, Wang L, et al
    Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis.
    Oncol Rep. 2018 Aug 20. doi: 10.3892/or.2018.6661.
    PubMed     Text format     Abstract available


  20. DIAO X, Chen X, Pi Y, Zhang Y, et al
    Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.
    Oncol Rep. 2018;40:1174-1184.
    PubMed     Text format     Abstract available


    July 2018
  21. LIN JZ, Hameed I, Xu Z, Yu Y, et al
    Efficacy of gefitinibcelecoxib combination therapy in docetaxelresistant prostate cancer.
    Oncol Rep. 2018 Jul 24. doi: 10.3892/or.2018.6595.
    PubMed     Text format     Abstract available


    June 2018
  22. XU M, Jaing H, Wang H, Liu J, et al
    SB225002 inhibits prostate cancer invasion and attenuates the expression of BSP, OPN and MMP2.
    Oncol Rep. 2018 Jun 18. doi: 10.3892/or.2018.6504.
    PubMed     Text format     Abstract available


  23. KOU R, Zhao J, Gogoi P, Carskadon S, et al
    Enrichment and mutation detection of circulating tumor cells from blood samples.
    Oncol Rep. 2018;39:2537-2544.
    PubMed     Text format     Abstract available


    May 2018
  24. TANG Q, Ma J, Sun J, Yang L, et al
    Genistein and AG1024 synergistically increase the radiosensitivity of prostate cancer cells.
    Oncol Rep. 2018 May 30. doi: 10.3892/or.2018.6468.
    PubMed     Text format     Abstract available


    April 2018
  25. LIU Z, Zhang H, Ding S, Qi S, et al
    betaKlotho inhibits androgen/androgen receptorassociated epithelialmesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.
    Oncol Rep. 2018 Apr 25. doi: 10.3892/or.2018.6399.
    PubMed     Text format     Abstract available


  26. YANG A, Zhao Y, Wang Y, Zha X, et al
    Huaier suppresses proliferative and metastatic potential of prostate cancer PC3 cells via downregulation of Lamin B1 and induction of autophagy.
    Oncol Rep. 2018 Apr 5. doi: 10.3892/or.2018.6358.
    PubMed     Text format     Abstract available


    March 2018
  27. CHEN Q, Zhu L, Zong H, Song X, et al
    Subcellular localization of aquaporin 3 in prostate cancer is regulated by RalA.
    Oncol Rep. 2018 Mar 9. doi: 10.3892/or.2018.6308.
    PubMed     Text format     Abstract available


  28. XU S, Ge J, Zhang Z, Zhou W, et al
    miR-141 inhibits prostatic cancer cell proliferation and migration, and induces cell apoptosis via targeting of RUNX1.
    Oncol Rep. 2018;39:1454-1460.
    PubMed     Text format     Abstract available


    January 2018
  29. CAI C, He H, Duan X, Wu W, et al
    miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression.
    Oncol Rep. 2018 Jan 31. doi: 10.3892/or.2018.6240.
    PubMed     Text format     Abstract available


  30. LAI Y, Kong Z, Zeng T, Xu S, et al
    PARP1-siRNA suppresses human prostate cancer cell growth and progression.
    Oncol Rep. 2018 Jan 26. doi: 10.3892/or.2018.6238.
    PubMed     Text format     Abstract available


    November 2017
  31. LIU T, Qiu X, Zhao X, Yang R, et al
    Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
    Oncol Rep. 2017 Nov 29. doi: 10.3892/or.2017.6121.
    PubMed     Text format     Abstract available


  32. WA Q, Li L, Lin H, Peng X, et al
    Downregulation of miR19a3p promotes invasion, migration and bone metastasis via activating TGFbeta signaling in prostate cancer.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6096.
    PubMed     Text format     Abstract available


  33. KUBO M, Satoh T, Ishiyama H, Tabata KI, et al
    Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy.
    Oncol Rep. 2017 Nov 13. doi: 10.3892/or.2017.6095.
    PubMed     Text format     Abstract available


  34. ZOU P, Yang Y, Xu X, Liu B, et al
    Silencing of vacuolar ATPase c subunit ATP6V0C inhibits the invasion of prostate cancer cells through a LASS2/TMSG1-independent manner.
    Oncol Rep. 2017 Nov 10. doi: 10.3892/or.2017.6092.
    PubMed     Text format     Abstract available


  35. SZYSZKA M, Tyczewska M, Milecka P, Jopek K, et al
    Effects of leptin on leptin receptor isoform expression and proliferative activity in human normal prostate and prostate cancer cell lines.
    Oncol Rep. 2017 Nov 1. doi: 10.3892/or.2017.6066.
    PubMed     Text format     Abstract available


    October 2017
  36. KOU B, Liu W, Zhao W, Duan P, et al
    Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-beta/Smad2/3 signaling pathway.
    Oncol Rep. 2017 Oct 2. doi: 10.3892/or.2017.6012.
    PubMed     Text format     Abstract available


    September 2017
  37. NOWACKA-ZAWISZA M, Wisnik E
    DNA methylation and histone modifications as epigenetic regulation in prostate cancer (Review).
    Oncol Rep. 2017 Sep 20. doi: 10.3892/or.2017.5972.
    PubMed     Text format     Abstract available


  38. ZHOU Y, Gu P, Li J, Li F, et al
    Suppression of STIM1 inhibits the migration and invasion of human prostate cancer cells and is associated with PI3K/Akt signaling inactivation.
    Oncol Rep. 2017 Sep 18. doi: 10.3892/or.2017.5961.
    PubMed     Text format     Abstract available


  39. LING Z, Liu D, Zhang G, Liang Q, et al
    miR-361-5p modulates metabolism and autophagy via the Sp1-mediated regulation of PKM2 in prostate cancer.
    Oncol Rep. 2017;38:1621-1628.
    PubMed     Text format     Abstract available


    August 2017
  40. KHURANA N, Kim H, Chandra PK, Talwar S, et al
    Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Oncol Rep. 2017 Aug 30. doi: 10.3892/or.2017.5932.
    PubMed     Text format     Abstract available


    July 2017
  41. GAO C, Zhou Y, Jiang Z, Zhao Y, et al
    Cytotoxic and chemosensitization effects of Scutellarin from traditional Chinese herb Scutellaria altissima L. in human prostate cancer cells.
    Oncol Rep. 2017 Jul 24. doi: 10.3892/or.2017.5850.
    PubMed     Text format     Abstract available


  42. ZHOU Y, Ji Z, Yan W, Zhou Z, et al
    The biological functions and mechanism of miR212 in prostate cancer proliferation, migration and invasion via targeting Engrailed-2.
    Oncol Rep. 2017 Jul 12. doi: 10.3892/or.2017.5805.
    PubMed     Text format     Abstract available


    June 2017
  43. ZHOU Y, Ji Z, Yan W, Zhou Z, et al
    Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.
    Oncol Rep. 2017 Jun 29. doi: 10.3892/or.2017.5768.
    PubMed     Text format     Abstract available


  44. XUAN Q, Zhong X, Li W, Mo Z, et al
    CtBP2 is associated with angiogenesis and regulates the apoptosis of prostate cancer cells.
    Oncol Rep. 2017 Jun 28. doi: 10.3892/or.2017.5763.
    PubMed     Text format     Abstract available


    May 2017
  45. HATA S, Nomura T, Iwasaki K, Sato R, et al
    Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer.
    Oncol Rep. 2017 May 24. doi: 10.3892/or.2017.5669.
    PubMed     Text format     Abstract available


  46. LIU L, Lou N, Li X, Xu G, et al
    Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Oncol Rep. 2017 May 4. doi: 10.3892/or.2017.5623.
    PubMed     Text format     Abstract available


  47. BAI S, Chen T, Yu X, Luo M, et al
    The specific killing effect of matrine on castration-resistant prostate cancer cells by targeting the Akt/FoxO3a signaling pathway.
    Oncol Rep. 2017;37:2819-2828.
    PubMed     Text format     Abstract available


    April 2017
  48. YIN B, Liu Z, Wang Y, Wang X, et al
    RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells.
    Oncol Rep. 2017 Apr 19. doi: 10.3892/or.2017.5585.
    PubMed     Text format     Abstract available


    March 2017
  49. ZHAO Y, Yan M, Yun Y, Zhang J, et al
    MicroRNA-455-3p functions as a tumor suppressor by targeting eIF4E in prostate cancer.
    Oncol Rep. 2017 Mar 13. doi: 10.3892/or.2017.5502.
    PubMed     Text format     Abstract available


  50. BAI Y, Xiao Y, Dai Y, Chen X, et al
    Stanniocalcin 1 promotes cell proliferation via cyclin E1/cyclindependent kinase 2 in human prostate carcinoma.
    Oncol Rep. 2017 Mar 13. doi: 10.3892/or.2017.5501.
    PubMed     Text format     Abstract available


  51. ZHANG H, Du X, Sun TT, Wang CL, et al
    Lectin PCL inhibits the Warburg effect of PC3 cells by combining with EGFR and inhibiting HK2.
    Oncol Rep. 2017;37:1765-1771.
    PubMed     Text format     Abstract available


    February 2017
  52. KONG Q, Chen XS, Tian T, Xia XY, et al
    MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein.
    Oncol Rep. 2017;37:803-812.
    PubMed     Text format     Abstract available


    January 2017
  53. SUN W, Guo L, Shao G, Liu X, et al
    Suppression of LASP-1 attenuates the carcinogenesis of prostatic cancer cell lines: Key role of the NF-kappaB pathway.
    Oncol Rep. 2017;37:341-347.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: